Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 17, 2011

Primary Completion Date

February 9, 2012

Study Completion Date

February 9, 2012

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Placebo

Take 4 capsules twice daily 12 hours apart with water. Swallow whole.

DRUG

PF-04136309

Take 4 capsules twice daily 12 hours apart with water. Swallow whole.

Trial Locations (10)

0

The Chinese University of Hong Kong,, Prince of Wales Hospital, Shatin, New Territories,

The University of Hong Kong,, Hong Kong

100

National Taiwan University Hospital, Taipei

807

Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung City

169608

Singapore General Hospital, Singapore

560017

Manipal Hospital, Bangalore

400 012

Seth G. S. Medical College & King Edward Memorial Hospital,, Mumbai

110 070

Institute of Liver & Biliary Sciences, New Delhi

110-744

Seoul National University Hospital, Department of Internal Medicine, Seoul

120-752

Severance Hospital, Yonsei University College of Medicine, Division of Gastroenterology, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY